PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Celea Therapeutics dosed the first patient in its global Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis (IPF). This is a positive clinical milestone toward potential late-stage results, though no efficacy or financial impact is provided in the report.

Analysis

Celea Therapeutics dosed the first patient in its global Phase 3 SURPASS-IPF trial evaluating deupirfenidone for idiopathic pulmonary fibrosis (IPF). This is a positive clinical milestone toward potential late-stage results, though no efficacy or financial impact is provided in the report.